Showing 3951-3960 of 8742 results for "".
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older
- Nebraska Gets “SUNucated”https://practicaldermatology.com/news/nebraska-gets-sunucated/2460116/Nebraska is the latest state to recommend that children be allowed to possess and use sunscreen without a doctor’s note at school and at school-sponsored events. “I am thrilled that Nebraska is stepping up to the plate with commonsense information that will now be con
- New AAD, NPF Guidelines Address Psoriasis Phototherapyhttps://practicaldermatology.com/news/new-aad-npf-guidelines-address-psoriasis-phototherapy/2460109/New guidelines from the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) take on psoriasis phototherapy. The
- New Cerave Poll Reveals Confusion about Healthy, Clean Skin and How to Achieve Ithttps://practicaldermatology.com/news/new-cerave-poll-reveals-confusion-about-healthy-clean-skin-and-how-to-achieve-it/2460108/Many of us are confused about what "clean" skin really means and how best to achieve it, according to an online survey commissioned by CeraVe.
- Summer AAD News: Understanding the Dermatologist’s Role in Reducing Skin-related Side Effects from New Cancer Drugshttps://practicaldermatology.com/news/summer-aad-news-understanding-the-dermatologists-role-in-reducing-skin-related-side-effects-from-new-cancer-drugs/2460107/While a new wave of targeted therapies are helping patients fight cancer, they also produce side effects that can affect patients’ hair, skin and nails that can greatly impact patients’ quality of life and threaten their ability to continue treatment. “Approximat
- Summer AAD News: Hyperhidrosis Updatehttps://practicaldermatology.com/news/summer-aad-news-hyperhidrosis-update/2460106/At least 15 million people in the U.S. experience diminished quality of life due to hyperhidrosis, yet half of people with the condition delay treatment for 10 years or more, according to information presented at the 2019 American Academy of Dermatology Summer Meeting in New York City.
- Summer AAD News: Dramatic Spike in Female Skin Cancer Linked to Tanninghttps://practicaldermatology.com/news/summer-aad-news-dramatic-spike-in-female-skin-cancer-linked-to-tanning/2460105/Skin cancer in women is on the rise, and indoor tanning may be to blame, according to new research presented at the 2019 American Academy of Dermatology Summer Meeting in New York City. Between 1970 and 2009, rates of melanoma increased 800 percent among women ages 18-39, making it the
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 S
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Bo
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.